JP2009526833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526833A5 JP2009526833A5 JP2008554881A JP2008554881A JP2009526833A5 JP 2009526833 A5 JP2009526833 A5 JP 2009526833A5 JP 2008554881 A JP2008554881 A JP 2008554881A JP 2008554881 A JP2008554881 A JP 2008554881A JP 2009526833 A5 JP2009526833 A5 JP 2009526833A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amisulpride
- prodopaminergic
- indirect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 10
- 229960003036 amisulpride Drugs 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 8
- 230000003291 dopaminomimetic effect Effects 0.000 claims 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 6
- 229960001736 buprenorphine Drugs 0.000 claims 6
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 5
- 229960000938 nalorphine Drugs 0.000 claims 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229960001797 methadone Drugs 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000037406 food intake Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960001534 risperidone Drugs 0.000 claims 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 2
- 229960003086 naltrexone Drugs 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 1
- NTJOBXMMWNYJFB-LBPRGKRZSA-N 4-amino-n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-LBPRGKRZSA-N 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 229960000263 levallorphan Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004503 metoclopramide Drugs 0.000 claims 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960004940 sulpiride Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FR2006/000372 WO2007096489A1 (fr) | 2006-02-17 | 2006-02-17 | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| PCT/IB2007/000390 WO2007093909A1 (fr) | 2006-02-17 | 2007-02-19 | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement globla des addictions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526833A JP2009526833A (ja) | 2009-07-23 |
| JP2009526833A5 true JP2009526833A5 (enExample) | 2010-04-08 |
Family
ID=37054597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554881A Withdrawn JP2009526833A (ja) | 2006-02-17 | 2007-02-19 | 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110039834A1 (enExample) |
| EP (2) | EP1988883A1 (enExample) |
| JP (1) | JP2009526833A (enExample) |
| CN (1) | CN101420944A (enExample) |
| AU (1) | AU2007216255A1 (enExample) |
| CA (1) | CA2642561A1 (enExample) |
| WO (2) | WO2007096489A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| JP6158810B2 (ja) * | 2011-08-18 | 2017-07-05 | バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CA3175428A1 (en) * | 2020-04-13 | 2021-10-21 | aiberry, Inc. | Multimodal analysis combining monitoring modalities to elicit cognitive states and perform screening for mental disorders |
| CN112245434A (zh) * | 2020-11-09 | 2021-01-22 | 深圳善康医疗健康产业有限公司 | 一种纳曲酮和利培酮复方缓释组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| CZ296263B6 (cs) * | 1996-03-25 | 2006-02-15 | Eli Lilly And Company | Farmaceutická kompozice pro lécení bolesti a jejípouzití |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| EP1644335A4 (en) * | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| EP1670460B1 (en) * | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| PT1697371E (pt) * | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| US20050181071A1 (en) * | 2004-02-18 | 2005-08-18 | Binder Michael R. | Method for the treatment of clinical depression |
| FR2877573B1 (fr) * | 2004-11-05 | 2007-02-02 | Debussy Holding Sa | Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues |
-
2006
- 2006-02-17 EP EP06725976A patent/EP1988883A1/fr not_active Withdrawn
- 2006-02-17 WO PCT/FR2006/000372 patent/WO2007096489A1/fr not_active Ceased
-
2007
- 2007-02-19 AU AU2007216255A patent/AU2007216255A1/en not_active Abandoned
- 2007-02-19 WO PCT/IB2007/000390 patent/WO2007093909A1/fr not_active Ceased
- 2007-02-19 US US12/278,622 patent/US20110039834A1/en not_active Abandoned
- 2007-02-19 CA CA002642561A patent/CA2642561A1/fr not_active Abandoned
- 2007-02-19 EP EP07705612A patent/EP2015739A1/fr not_active Withdrawn
- 2007-02-19 JP JP2008554881A patent/JP2009526833A/ja not_active Withdrawn
- 2007-02-19 CN CNA2007800136067A patent/CN101420944A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU725556B2 (en) | Method for treating pain | |
| RU2428985C2 (ru) | Лекарственная форма, содержащая оксикодон и налоксон | |
| WO2011008298A2 (en) | Novel axomadol dosage forms | |
| JP2013528588A (ja) | ニコチン含有医薬組成物 | |
| EA023807B1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
| RU2226107C2 (ru) | Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса | |
| CN101073563B (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
| JP2019116494A (ja) | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| TW200427448A (en) | Controlled release preparations comprising tramadol and topiramate | |
| JP6174666B2 (ja) | ナルトレキソンの徐放型配合物 | |
| CA2671954A1 (en) | Methods for treating or preventing symptoms of hormonal variations | |
| WO2012048294A2 (en) | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy | |
| CN101588797A (zh) | 带有最小化副作用包括减轻肝毒性的对乙酰氨基酚组合物 | |
| JP2009526833A5 (enExample) | ||
| CN106999454A (zh) | 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛 | |
| TW200946142A (en) | Tablet | |
| JP2013510841A5 (enExample) | ||
| EP3741369A1 (en) | Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate | |
| JP2019535758A (ja) | リドカイン無効状態および低カリウム血症状態の治療のための療法 | |
| JP2005513105A5 (enExample) | ||
| WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
| JP2008519016A5 (enExample) | ||
| JP2007528891A (ja) | 複合鎮痛剤医薬組成物 | |
| CN100566716C (zh) | 治疗高血脂症的组合物 |